Immune Checkpoint Bioassays

Our industry leading bioassays can accelerate your immunotherapy drug development. Whether you’re targeting immune checkpoint co-inhibitory, co-stimulatory, or a combination of receptors, we have the tools to meet your needs. Our robust collection of assays can be used in a variety of settings, from antibody screening and characterization, to potency and stability determination and QC lot release.  

MyGlo Instrument now $4950. Use code GETMYGLO at checkout to get 10% off MyGlo. Shop Now ›

Filter By

Immune Checkpoint Bioassays

Shop all Immune Checkpoint Bioassays

Showing 23 of 23 Products

LAG-3/MHCII Blockade Bioassay

Ghosh, S. et al. (2019) TSR-033, a novel therapeutic Ab targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo. Mol. Cancer Ther. 18, 632–641. doi: 10.1158/1535-7163.MCT-18-0836


PD-1/PD-L1 Blockade Bioassay

Rattanapisit, K. et al. (2019) Structural and in vitro functional analyses of novel plant-produced anti-human PD1 antibody. Sci. Rep. 9, 15205. doi: 10.1038/s41598-019-51656-1


CTLA-4 Blockade Bioassay, PD-1/PD-L1 Blockade Bioassay, OX40 Bioassay

Simons, J.F. et al. (2020) Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR. mAbs 12(1), 1803646. doi: 10.1080/19420862.2020.1803646

An Introduction to Immune Checkpoint Receptors

The immune system is comprised of a complex network of co-inhibitory and co-stimulatory pathways that help to maintain homeostasis and prevent autoimmunity. Under typical conditions, these immune checkpoints allow appropriate immune response to infections and malignancies while protecting healthy tissues from harm. 

Inhibitory immune checkpoint receptors (including PD-1, CTLA-4, TIGIT, LAG-3, and TIM-3) expressed on activated T cells and B cells play a critical role in regulating immune responses to tumor antigens and autoantigens. Engagement of a receptor by its ligand on an adjacent cell inhibits T-cell receptor (TCR) signaling and TCR-mediated proliferation, transcriptional activation and cytokine production. Therapeutic antibodies and Fc fusion proteins designed to block the receptor-ligand interaction show promising results in clinical trials for the treatment of a variety of cancers.

Co-stimulatory immune checkpoint receptors (including GITR, OX40, CD40, 4-1BB, and ICOS) are expressed on T cells. Therapeutic antibodies designed to activate these immune checkpoint receptors and enhance immune signaling are also emerging as a promising strategy for cancer therapy. 

Cell-based functional reporter bioassays are critical to the development and characterization of antibody based biologic drugs targeting immune checkpoint receptors.